Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study

Shireen Meher1,2, Anna Cuthbert1, Jamie J Kirkham1, Paula Williamson3, Edgardo Abalos4, Nasreen Alfaifel1, Zulfiqar A Bhutta5, Alina Bishop6, Jennifer Blum7, Peter Collins8, Declan Devane9, Anne-Sophie Ducloy-Bouthors10, Bukola Fawole11, A Metin Gülmezoglu12, Kathryn Gutteridge2, Gill Gyte6, Caroline SE Homer13, Shuba Mallaiah14, Jeffrey M Smith15, Andrew D Weeks1, Zarko Alfirevic1.

1 Department of Women’s and Children’s Health, University of Liverpool, UK, 2 Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK, 3 Department of Biostatistics, University of Liverpool, UK, 4 Centro Rosarino de Estudios Perinatales (CREP), Rosario, Argentina, 5 Division of Women and Child Health, Aga Khan University, Pakistan, 6 Cochrane Pregnancy and Childbirth Group, University of Liverpool, UK, 7 Gynuity Health Projects, New York, USA, 8 Institute of Infection and Immunity, School of Medicine Cardiff University, UK, 9 HRB-Trials Methodology Research Network, School of Nursing and Midwifery, National University of Ireland Galway, Ireland, 10 Centre Hospitalier Regional Universitaire de Lille, France, 11 Department of Obstetrics and Gynaecology, College of Medicine, University of Ibadan, Nigeria, 12 The UNDP/UNFPA/UNICEF/WHO/World Bank Special programme of research, development and research training in human reproduction (HRP), World Health Organization, Geneva, Switzerland, 13 Centre for Midwifery, Child and Family Health, University of Technology Sydney, Australia, 14 Liverpool Women’s Hospital, Liverpool, UK, 15 Jhpiego / Johns Hopkins University, USA.

Corresponding author
Shireen Meher, +44 (0)7734694660, smeher@liv.ac.uk

Short title: PPH Core Outcome Sets
ABSTRACT

Objective: To develop core outcome sets (COS) for studies evaluating interventions for (1) prevention and (2) treatment of PPH, and recommendations on how to report the COS.

Design: A two-round Delphi survey and face-to-face meeting.

Population: Health care professionals and women’s representatives.

Methods: Outcomes were identified from systematic reviews of PPH studies and stakeholder consultation. Participants scored each outcome in the Delphi on a Likert scale between 1 (not important) and 9 (critically important). Results were discussed at the face-to-face meeting to agree the final COS. Consensus at the meeting was defined as ≥ 70% of participants scoring the outcome as critically important (7-9). Lectures, discussion and voting were used to agree how to report COS outcomes.

Main outcome measures: outcomes from systematic reviews and consultations.

Results: Both Delphi rounds were completed by 152/205 (74%) participants for prevention and 143/197 (73%) for treatment. For prevention of PPH, nine core outcomes were selected: blood loss, shock, maternal death, use of additional uterotonics, blood transfusion, transfer for higher level of care, women’s sense of wellbeing, acceptability and satisfaction with the intervention, breastfeeding and adverse effects. For treatment of PPH, 12 core outcomes were selected: blood loss, shock, coagulopathy, hysterectomy, organ dysfunction, maternal death, blood transfusion, use of additional haemostatic intervention, transfer for higher level of care, women’s sense of wellbeing, acceptability and satisfaction with the intervention, breastfeeding and adverse effects. Recommendations were developed on how to report these outcomes where possible.

Conclusions: These COS will help standardise outcome reporting in PPH trials.

Funding: British Medical Association (Strutt and Harper Grant 2014).

Keywords: core outcomes, postpartum haemorrhage, PPH, pregnancy, Delphi

Tweetable abstract: Core outcome sets for PPH: 9 core outcomes for PPH prevention and 12 core outcomes for PPH treatment.
INTRODUCTION

Over 250,000 women die each year from complications of childbirth. PPH is the leading cause of maternal mortality worldwide. It is usually defined as blood loss of 500 ml or more from the genital tract within 24 hours after childbirth.

Interventions for PPH have been evaluated in a large number of studies. However evidence is difficult to interpret and compare across studies due to variations in the outcomes measured by researchers. In a study looking at outcomes reported in PPH trials published between 1997 and 2015, 121 trials for prevention of PPH used 68 different primary outcomes. The most commonly reported outcome was assessment of blood loss, with more than ten different cut-offs specified at times ranging from 30 minutes to 48 hours. There were little data on short and long-term morbidity or mortality, and few patient reported outcomes.

Reduction in maternal mortality is part of the Sustainable Development Goals set by the United Nations. One strategy for achieving this is to ensure that the most effective evidence based therapies are used to manage PPH, and global standards follow evidence based guidelines. Recommendations can only be robust if they are based on good quality evidence, where interventions are compared using indicators that are standardized and are important measures of wellbeing.

The aim of this project was to develop consensus among international stakeholders on a set of core outcomes that should be used in trials and systematic reviews to evaluate (1) preventative interventions and (2) therapeutic interventions for women with PPH. A secondary aim was to provide guidance on how to report these core outcomes.

METHODS

The project was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET) initiative and funded by the British Medical Association (BMA). The protocol was peer-reviewed by the COMET team and funding body. Ethics approval was not required. The manuscript has been reported in line with the COS-STAR guidelines for COS reporting. Methods are summarised in Figure S1 and further details are available in Appendix S1.

The Steering Committee included two obstetricians (SM, ZA), a midwife (AC) and two methodologists/statisticians with expertise in development of COS (JK, PW). A Scientific Advisory Group (SAG) was set up to provide multidisciplinary expert input and an international perspective (16 members from 10 countries and seven stakeholder groups; Appendix S1). Seven stakeholder groups were agreed a priori to be relevant to the project (obstetricians, midwives, anaesthetists, haematologists, neonatologists, health strategists/methodologists and women’s representatives).
1. Identification of participants for the Delphi Survey

Our aim was to involve as many participants as possible, with a minimum of 10 in each stakeholder group to allow numbers to be meaningful taking into account possible attrition in Round 2. The same participants were asked to take both the prevention and treatment PPH surveys. Participants were identified from published trial reports and Cochrane reviews on PPH. Invitations were also sent through the CoRe Outcomes in Women’s and Newborn health (CROWN) Initiative journal editors mailing list. Women’s representatives were invited through the National Childbirth Trust parent support group (UK) and personal contacts. Further invitations to stakeholders were sent out by snowballing with suggestions from the SAG, authors contacted and targeted participants. The SAG also took a modified Delphi survey separately. This was a methodological investigation to assess the impact of group size and number of panels on selection of outcomes for a COS, and will be the subject of a separate paper.

2. Identification of outcomes

To identify outcomes relevant to PPH, two systematic reviews of randomized trials were undertaken - one evaluating interventions for prevention of PPH (NA and ZA), the other, treatment of PPH (SM and ZA) (details in Appendix S1). All published outcomes were considered for inclusion in the COS.

The reviews identified 121 randomised trials with 160 different outcomes for prevention of PPH and 16 RCTs with 95 different outcomes for treatment of PPH. Outcomes were classified under overarching domains (blood loss assessment, mortality and morbidity, use of additional interventions and resources, women’s and clinicians’ views, adverse outcomes, and neonatal outcomes). Duplicate outcomes were removed, similar outcomes combined and variations in methods of reporting each outcome noted (Tables S1 and S2). Two outcomes - women’s and healthcare professionals’ views, were added by the Steering Committee. A total of 35 outcomes for prevention of PPH and 31 outcomes for treatment of PPH were entered into Round 1 of the Delphi.

3. Delphi Survey

A two-round, anonymised electronic Delphi survey was designed on DelphiManager to obtain consensus on the importance of each outcome among stakeholders. It was decided a priori that results of the Delphi would be used to inform the face-to-face stakeholder meeting where a final COS would be agreed.

Each outcome was listed in the survey with its plain language summary. Participants were asked to rate the importance of each outcome between 1 and 9 on a Likert scale, with 1-3 being ‘not important’, 3-6 ‘important but not critical’ and 7-9 being ‘critically important’ to report in trials, or select unable to comment. This scale is recommended by the Grading of Recommendations Assessment, Development and Evaluation working group. Participants were invited to suggest additional outcomes for consideration for the COS in Round 1 using free-text responses.

Potential participants were invited to register for the study via email, and the Delphi survey was emailed to those who registered. The closing date was set 4 weeks after each round and an e-mail reminder was sent
on days 14, 21, and 28. Non-responders in Round 1 were not invited to participate in Round 2. Non-
responders in Round 2 were sent additional emails to improve response rate.

In Round 2, participants were able to view anonymised results from the first round, presented as the
distribution of scores for each outcome in each stakeholder group separately. This allowed participants to
reflect on their choices prior to completing the second round of the survey. Additional relevant outcomes
suggested by participants in Round 1 were added to Round 2 (16 for prevention and 18 for treatment)
(Figures S2 and S3).

We defined consensus for the Delphi a priori based on guidance in The COMET Handbook. For inclusion
in the COS, outcomes required at least 70% of participants in each stakeholder group to score the outcome
as critically important and less than 15% to score the outcome as not important. Outcomes excluded from
the COS required at least 70% of participants in each stakeholder group to score the outcome as not
important and less than 15% to score the outcome as "critical." If outcomes did not meet either criterion
they were classified as outcomes with no consensus.

4. Face-to-face meeting
The final phase of the project was a face-to-face consensus meeting (Liverpool, United Kingdom 16-17th
August 2016). Twenty-five people attended the meeting, and each stakeholder group was represented: five
obstetricians, three midwives, four women’s representatives, five health strategist/methodologists, one
anaesthetist, one haematologist, and one neonatologist (Appendix S1). Findings of the survey were
presented and participants were given an opportunity to discuss each outcome. Consideration was given as
to whether the outcome was relevant in all setting and for all women recruited. Outcomes could be re-
named or reconfigured if there was full consensus at the meeting to do so. Participants then scored each
outcome between 1 and 9 on the Likert scale, for inclusion or exclusion in the COS with an anonymous
voting system using electronic keypads. Consensus at the meeting required a majority of 70% of
participants to score the outcome as critically important (7-9) to include in the COS.

5. Methodology for how to report outcomes
Consensus on how to report the COS outcomes was developed on Day 2 of the meeting by an Expert
Committee (n=20; Appendix S1). The aim was not to create new definitions but to select a preferred
method of reporting the outcome among existing methods in published literature where possible and to
make research recommendations where this was not possible.

We used recommended standards on how to report summary results for trial reporting and considered the
specific metric on how to measure the outcome, the method of data aggregation (continuous or categorical)
and the time frame in which to measure the outcome. Variations in outcome reporting were presented and
expert presentations delivered. Options were discussed, and scored. Consensus was defined a priori as
more than 70% of participants voting for a preferred option of reporting, and majority view was defined as
more than 50% of participants preferring one option from among the top three options, thereby indicating
the strength of the recommendation.

RESULTS

Survey participants came from 36 different countries (Figure S4), and represented all seven stakeholder groups. For Round 1 of the Delphi, 205 participants responded to the prevention of PPH survey and 197 to the treatment survey. Round 2 was completed by 74% (152/205) and 73% (143/197) of participants respectively (Table 1). Overall, 77% of those who took the survey had exposure to PPH either through personal experience or through caring for women who had experienced PPH. Among women’s representatives, 41% had experienced a PPH.

Assessment of outcomes for the prevention and treatment of PPH COS is shown in Figure 1. Delphi consensus was reached for including five outcomes in the COS for prevention of PPH and ten outcomes in the COS for treatment of PPH. No outcomes fulfilled criteria for exclusion. There was no consensus on the remaining outcomes. After discussing these results at the face-to-face meeting, the final COS included nine outcomes for prevention and 12 outcomes for treatment of PPH. At least one outcome from each domain was included in both COS, and there was significant overlap in outcomes included between the two COS.

1. PPH Prevention COS

For the evaluation of interventions for prevention of PPH, the final COS outcomes are presented in Table 2. At the stakeholder meeting, all outcomes that met the Delphi consensus criteria were included in the COS except for hysterectomy. Although stakeholders at the meeting agreed that hysterectomy was an important outcome, it was not felt to be critically important in the context of trials for PPH prevention because it is a very rare event. Although rare but critically important outcomes are also important to include in a COS, and such an outcome of maternal mortality has been included, there was consensus that the PPH prevention COS would be more informative if it captured other measures of maternal morbidity for which data were more likely to be available from trials rather than having a COS with little data available for multiple outcomes. Blood loss was thought to be an important outcome for PPH trials to report, although difficulties in assessing it were acknowledged. Four additional outcomes were included in the PPH prevention COS subsequent to stakeholder discussions and voting. Two of these outcomes, ‘use of blood transfusion’ and ‘use of additional uterotonics’ were borderline for inclusion in the Delphi survey (Table 2). The outcomes ‘transfer to ITU’ and ‘transfer to a higher facility’ in the Delphi were reconfigured at the stakeholder meeting to ‘transfer to a higher level of care’ to capture data on an escalation in the level of care required for the woman, which, it was recognized, would depend on the initial setting of the woman. There was also consensus among stakeholders at the meeting that patient reported outcomes, although not included in the Delphi consensus, were important to include in the COS, and this was strongly advocated by the women’s representatives. It was felt that these should capture a woman’s sense of wellbeing, as well as acceptability and satisfaction with the intervention. Among outcomes in the neonatal domain, there was consensus that breastfeeding would be an important outcome as a PPH may impact on a woman’s wellness and ability to establish or maintain breastfeeding if she
intended to breastfeed, or there could be a potential impact of the intervention on breast milk itself.

2. PPH Treatment COS
For the evaluation of interventions for treatment of PPH, the final COS is presented in Table 3. Nine of the 10 outcomes that met the Delphi consensus criteria were included in the final COS. Two very similar outcomes - ‘shock’ and ‘maternal resuscitation due to shock’ - were both included by the Delphi survey. Hence, consensus at the stakeholder meeting was to include ‘shock’ only in preference to ‘maternal resuscitation due to shock’ as the latter would be more complex to measure. The outcome disseminated intravascular coagulation, (DIC) was renamed as coagulopathy based on recommendations by haematologists because coagulopathy is the more accurate term; DIC does not have a validated definition in PPH and constitutes only a small subset of coagulopathies associated with PPH. Multiple organ failure was renamed as ‘any organ dysfunction’, in line with the World Health Organization’s recommendations on how to capture severe pregnancy complications including organ dysfunction in the WHO near-miss approach for maternal health. A number of outcomes in the Delphi survey aimed at capturing failure of initial treatment, such as use of additional medical or advanced surgical interventions such as balloon insertion or uterine artery embolisation or ligation. However, at the meeting it was recognized that type of escalation of therapy would depend on the trial intervention itself – medical or surgical. Therefore, these outcomes were reconfigured into the outcome ‘Use of any additional haemostatic intervention’ to capture failure of the trial intervention itself, as this would be applicable to all trials, regardless of the intervention they were evaluating. The other outcomes added were a woman’s sense of wellbeing and acceptability and satisfaction with the intervention, and breastfeeding as specified above in the prevention of PPH COS.

3. How to report COS outcomes
The Expert Committee Recommendations on how to report the COS outcomes are presented in Table 4, along with explanations. Most recommendations were agreed by consensus. Those agreed by majority view included reporting of hysterectomies specifically carried out to stop PPH, to avoid confounding data with hysterectomies carried out prophylactically or for other indications. For time frames for measuring outcomes, there was consensus that in the context of randomised trials outcome data should be collected from the point of randomisation. The time limit up to which outcomes should be measured was left to trialists for most outcomes to accommodate for local protocols and resource availability. However a majority view recommendation was put forward for blood loss to be assessed (measured or estimated) up to cessation of active bleeding, as this is an area where standardization is particularly lacking and time frame selection is likely to impact on data significantly. For hysterectomy, the majority recommendation was to report it at least up to hospital discharge as most hysterectomies are likely to occur by that time in the context of PPH.

For the patient reported outcomes and breastfeeding, it was felt by the stakeholder groups that further work was needed to develop tools to capture what aspects of these outcomes were most important to women in the context of a PPH.
DISCUSSION

Main findings
Consensus on PPH COS was developed among an international panel of stakeholders through a Delphi survey and face-to-face meeting. For the evaluation of interventions for prevention of PPH, nine core outcomes were selected and for treatment of PPH, 12 core outcomes. Expert committee recommendations where developed on how to report each outcome where possible, and a research agenda was set for two outcomes where this was not possible.

Strengths and Limitations
This project has several strengths. Firstly, the methodology was defined a priori based on guidelines by the COMET Initiative. The Delphi exercise has the advantage of including views of a larger number of geographically distant participants. Participants in the Delphi were still able to consider the views of other stakeholder groups in Round 2, to reconsider their opinion without being overly influenced by domineering individuals. Results were further refined at the face-to-face meeting which allowed for rich discussions as well as the ability to debate and persuade others. Secondly, stakeholders came from a range of relevant specialties. Importantly, consumer representatives, who are sometimes overlooked in similar projects, were included at all stages of the process. There was representation from both those who had and had not experienced PPH. Our parent representatives impacted the final COS outcomes by influencing other stakeholders at the face-to-face meeting to include patient reported outcomes. Thirdly, there was representation from a wide range of countries of variable income status in the Delphi and at the face-to-face meeting, so that the COS developed would be applicable across different settings. Fourthly, we have developed COS for both prevention and treatment of PPH to cover the full spectrum of PPH intervention trials. It is not surprising that there is significant overlap in outcomes selected for the two COS. However the PPH treatment COS appropriately includes more outcomes that capture significant maternal morbidity in the presence of an established PPH. And finally, a COS often tells researchers what outcomes to use, but not how to report them, making it difficult to achieve adequate standardisation; we have developed Expert Committee Recommendations on how to report the outcomes selected for PPH COS to provide better guidance to researchers.

The limitations of this project are that outcomes were obtained largely from systematic reviews and participants in the Delphi exercise; we did not conduct formal interviews with women. Secondly, we asked participants to identify one key stakeholder group to which they belonged. Some participants may have belonged to more than one stakeholder group and this may have influenced how they scored outcomes, but data are not available to explore this further. Thirdly, representation from each stakeholder groups was not equal; this may have impacted on the outcomes selected. Finally, although we have developed guidance on how to report COS outcomes, these recommendations are from a small group of experts, and have not been subjected to the same rigorous Delphi process in a large group. However, it is debatable whether a Delphi process is the optimum method for developing consensus on how to report outcomes. More complex discussions may need to be undertaken for consensus on measurement instruments by stakeholders who
may be different from those partaking in the ‘what to measure’ Delphi. Generic methodological guidelines on how to select standardised instrument measures for outcomes have recently been published. They recommend identifying all possible measurement instruments for an outcome, and selecting one with high quality of evidence for good validity and internal consistency, that is feasible to measure in the target population. These guidelines have not yet been applied prospectively for COS in maternal health. Our systematic reviews identified the different ways in which COS outcomes have been reported, and the feasibility of applying the instruments in an international setting was considered when making recommendations on how to report outcomes. While validity may be excellent for the more objective outcomes included in the COS, such as units of blood transfusion or maternal death, measurement tools for other outcomes such as blood loss are well known for their poor accuracy.

**Interpretation**

To our knowledge, there is no other published COS for PPH. These COS include outcomes that capture meaningful morbidity (shock, hysterectomy, organ dysfunction) and mortality. They also include outcomes with high event rates upon which sample size calculations could be based for smaller studies (blood loss, use of additional uterotonics or blood transfusion). Resource use may be assessed through use of additional interventions and level of care such as ITU use. Patient reported outcomes (wellbeing and satisfaction) and breastfeeding are also captured but require further qualitative research on how best to measure these outcomes. Until further data are available, we would encourage researchers to clearly report the measures they have used.

Although these outcomes aim to assess the impact of interventions evaluated on severity of PPH, some outcomes may be influenced by local practices. For example, thresholds used for transfusing blood or transferring a woman for higher level of care may vary across trial settings and studies. For such outcomes we would encourage authors to interpret results bearing the potential impact of local practices in mind.

We would recommend researchers evaluating interventions for PPH to report these COS outcomes as a minimum, along with any other outcomes of interest to their study. Where these COS are not reported, researchers are encouraged to provide an explanation, for transparency and to reduce the risk of reporting bias. Future trials evaluating interventions for PPH should report any barriers identified to data collection for these COS outcomes. COS may be updated to provide guidance in response to such feedback.

**CONCLUSIONS**

The PPH COS, developed through an international multidisciplinary effort, will help standardise outcome reporting in this area, and facilitate comparison of data across studies, to guide clinical practice. We recommend that researchers evaluating interventions for PPH prevention and treatment should report these COS outcomes as a minimum, along with any other outcomes of interest. Further work is needed on how to best to report women’s sense of wellbeing, acceptability and satisfaction with the intervention and breastfeeding in the context of PPH.
ACKNOWLEDGEMENTS
We would like to acknowledge (1) participants of the Delphi survey (Appendix S2); (2) participants at the consensus meeting not in the authorship: Jim Neilson (chair), Joao Paulo Souza, Halima Shakur, Beverly Hunt, Julie Nycyk, Steven Lane, Michelle Beacock, Helen Castledine, Carolyn Markham; (3) the National Childbirth Trust, UK for facilitating women’s representation; (4) the Cochrane Pregnancy and Childbirth Group for facilitating the development of systematic reviews; (5) the COMET Initiative team for methodological support (6) the CROWN Initiative for circulating the Delphi survey and (7) the World Health Organisation for supporting and endorsing the project.

DISCLOSURE OF INTERESTS
The instrument for measurement of organ dysfunction and coagulopathy was adopted from the published WHO tool for assessing maternal morbidity. Although representatives from the WHO were involved in the project, this was a consensus decision by all participants at the meeting as it was felt that the tool was developed through a rigorous process, was feasible to apply in all settings and there were no better established alternative tools. ADW has a patent pending on the PPH Butterfly device for PPH management. JB reports grants from Bill and Melinda Gates Foundation during the conduct of the study; PC has grants from CSL Behring and Haemonetics, outside the submitted work; AD-B reports grants, personal fees and non-financial support from Laboratoire Fractionnement Biotechnologies, grants and non-financial support from French Ministry of health and drug administration ANSM, outside the submitted work; GG has received royalties from John Wiley & son in respect of ‘A Cochrane Pocketbook – Pregnancy and Childbirth’ Hofmeyr GJ et al. 2008. The remaining authors have no disclosures.

CONTRIBUTION OF AUTHORSHIP
SM and ZA conceived the idea and developed the protocol with PW. SM and AC executed the project with input from JK, PW and ZA. EA, NA, ZAB, AB, JB, PC, DD, AD-B, BF, AMG, KG, GG, CSEH, ShuM, JMS, ADW all took the SAG Delphi and provided expert input at various stages of the project. Data were analysed by AC and SM with input from JK and PW. SM wrote the manuscript with input from all co-authors.

DETAILS OF ETHICS APPROVAL
Ethics approval was not required as assessed by the MRC HRA tool as the study was not a clinical trial, did not assess a devise or expose patient to ionising radiation, did not require collection or storage of any material/specimens/protected information, recruit patients/carers through the NHS, involve anyone
with lack of capacity or prisoners, or xenotransplantation, and was not a social care project funded through
the Department of Health, UK.

FUNDING
This project was funded by the British Medical Association Strutt and Harper Grant. The funders reviewed
the application and protocol prior to awarding the grant, monitored the project progress, and provided
financial support to disseminate the COS through international meetings but were not directly involved in
any other aspect of the project.

REFERENCES
   10.1016/S2214-109X(14)70227-X.
3. Aflafeil, N. Postpartum haemorrhage: New insights from published trials and the development of
4. COMET Initiative. Core Outcome Sets for Prevention and Treatment of Postpartum Haemorrhage.
   [Accessed 1st March 2015].
   2017].
   Handbook: Version 1.0. Available from:
   https://trialsjournal.biomedcentral.com/track/pdf/10.1186/s13063-017-1978-
9. CROWN: Core Outcomes in Women’s and Newborn Health. Available from: http://www.crown-
   initiative.org/ [Accessed 15th June 2017],COMET Initiative.
    2017].


Appendix S1. Additional methods

1. Scientific Advisory Group (SAG)
SAG members were invited to participate based on their expertise in PPH or their own specialty, and were identified through previous involvement in international projects and publications or recommendations of experts. International representation from high, middle and low income countries was taken into consideration. At least one person from each stakeholder group was invited to join the SAG. Members included four obstetricians (EA, NA, BF, AW), three midwives (DD, KG, CH), three health strategists (JB, MG, JS), two anaesthetists (ASDB, ShuM), two women’s representatives (GG, AB), one haematologist (PC), and one neonatologist (ZAB). All members are co-authors of this report.

The SAG was also asked to take Round 1 of the Delphi survey separately, followed by a teleconference and then Round 2 on a limited number of outcomes that SAG members felt needed to be scored again after discussion. This was done as a methodological investigation to assess whether a small group of representative experts in a single multidisciplinary panel would select the same outcomes for a COS as a larger group of Delphi participants in multiple panels. Results of this investigation will be the subject of a separate paper. For PPH COS development, the SAG survey results were also presented at the face-to-face meeting as a separate stakeholder group.

2. Identification of outcomes

Methods for systematic reviews for prevention and treatment of PPH

Aim
To identify all outcomes reported in published RCTs evaluating interventions for
1. prevention of PPH
2. treatment of PPH

Inclusion Criteria
1. Types of studies: RCTs
2. Types of participants: women delivering at any gestation, regardless of risk of PPH were included.
   For prevention trials, women were included if they were pregnant or in the postnatal period, and for treatment trials postnatal women were included.
3. Types of interventions: We included all types of interventions given primarily for preventing PPH for the prevention review or treating primary PPH for the treatment review.
4. Types of outcomes: All published outcomes were included.

Search strategy
For the PPH prevention review, searches were conducted from January 1997, after publication of the first CONSORT statement, to December 2012. We searched the Cochrane Central of Controlled Trials
(CENTRAL), Embase, Medline, Web of knowledge and Scopus, for relevant RCTs using keywords and MeSH terms “postpartum hemorrhage, labour stage, third, ergovovine, misoprostol, medicine, Chinese traditional, Uterus and massage, carboprost, tranexamic acid, umbilical cord and uterus and pressuet”.

For the PPH treatment trials, searches were conducted from January 1997 until January 2015. We searched the Cochrane Pregnancy and Childbirth Group’s (PCG) Specialised Register for randomised trials relevant to PPH. The register is a database of citations to published and unpublished controlled clinical trials in perinatal medicine. It contains over 17,000 records, with an annual accrual of 1000 new records. The register is maintained by monthly searches of CENTRAL; weekly searches of MEDLINE and EMBASE; handsearches of 30 journals and the proceedings of major conferences; and weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. In addition, members of the Cochrane Collaboration contribute to the register from all around the world by sending in reports of RCTs retrieved through sources including local foreign language databases and personal communications. Details of the PCG search strategy can be found on [http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/PREG/frame.html](http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/PREG/frame.html). RCTs for this study were retrieved using the register’s codes for PPH treatment.

No language restrictions were applied. Titles and abstracts were screened and full papers for potentially eligible studies were retrieved. Studies were assessed for inclusion by two people independently (NA and ZA for prevention trials and SM and ZA for treatment trials) using the pre-specified criteria outlined in the methods section above. Any disagreements were resolved by discussion.

**Data Extraction and Analysis**

Data were collected on all reported outcomes from full papers of each publication on a pre-defined data extraction form. Data were entered into a Microsoft Excel database, double checked for accuracy, and analysed using Microsoft Excel.

**Results**

For the outcomes obtained from systematic reviews (n=160 for prevention and n=95 for treatment), clinicians in the Steering Committee (SM, ZA, AC) classified each outcome under overarching domains, to make them easier to present and interpret. Domains were developed to capture different themes across care of women with PPH, including blood loss assessment, mortality and morbidity, use of additional interventions and resources, women’s and clinicians’ views, adverse outcomes, and neonatal outcomes.

**3. Delphi Survey**

Plain language summaries were created for each outcome with input from a women’s representative (GG) to clarify what each outcome meant. The readability score was kept at ≤16. The survey was piloted by the steering committee. Minor changes were made in the survey structure.
Two email invitations were sent to all potential participants, one week apart to participate in the study. The email included a link that allowed them to register for the study. Personalised reminders were sent to maximise participation.

New outcomes suggested by participants in Round 1 were assessed for inclusion by the Steering Committee and SAG. Relevant outcomes were added to Round 2 (16 for prevention and 18 for treatment) (Figure S1 and Figure S2). Hence participants scored 51 outcomes for inclusion in the PPH prevention COS and 49 for the treatment COS in Round 2 of the Delphi and at the face-to-face meeting. Results were analysed on Microsoft Excel.

4. Face-to-face meeting
Invitations for the face-to-face meeting were based on 1) representation from each stakeholder group 2) international representation from high and low income countries 3) expertise in PPH and 4) feasibility of travel within funding available. Twenty-five people attended the meeting, including an independent chair and steering group members facilitating the meeting (n=4). Participants scoring outcomes (n=20) also included SAG members (n=14). Each stakeholder group was represented: five obstetricians, three midwives, four women’s representatives, five health strategists/methodologists, one anaesthetist, one haematologist, and one neonatologist.

Information material including Delphi results was sent to participants before the meeting. At the meeting, procedures and consensus criteria (defined a priori) were explained. Findings of the survey were presented for prevention and treatment of PPH separately, with discussion and agreement of the final COS for prevention in the first half of the day, and for treatment in the second half. For each outcome, the score distribution and overall score were presented by stakeholder group.

5. Methodology for how to report outcomes
The Expert Committee consisted of an independent chair and two steering committee members (SM, AC) to facilitate the meeting, and 17 voting participants: three obstetricians (AW, BF, EA), three midwives (DD, CH, KG), two anaesthetist (ASB, SM), one haematologist (BH), three health strategists (JB, JS, JPS), one methodologist (HS), two statisticians (JK, SL) and two women’s representatives (GG, AB).

Variations in the reporting of each included outcome were presented, based on data collected from the systematic reviews. Expert presentations were delivered on blood loss assessment, blood transfusion, assessment of shock/shock index, hysterectomy, and maternal death. Options were discussed, and scored using anonymised electronic touchpads. It was decided a priori that a research agenda would be developed where it was not possible to agree how to report an outcome or where further work was needed before guidance could be given.
Figure 1. Flowchart of outcomes for PPH COS
Table 1. Participants in Delphi survey by stakeholder group

<table>
<thead>
<tr>
<th>Stakeholder group</th>
<th>Prevention of PPH COS</th>
<th>Treatment of PPH COS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Round 1 n = 205 (%)</td>
<td>Round 2 n = 197 (%)</td>
</tr>
<tr>
<td></td>
<td>Round 2 n = 152 (%)</td>
<td>Round 2 n = 143 (%)</td>
</tr>
<tr>
<td>Anaesthetists</td>
<td>14 (7)</td>
<td>11 (7)</td>
</tr>
<tr>
<td></td>
<td>14 (7)</td>
<td>11 (8)</td>
</tr>
<tr>
<td>Haematologists</td>
<td>10 (5)</td>
<td>8 (5)</td>
</tr>
<tr>
<td></td>
<td>10 (5)</td>
<td>8 (6)</td>
</tr>
<tr>
<td>Midwives</td>
<td>28 (14)</td>
<td>21 (14)</td>
</tr>
<tr>
<td></td>
<td>27 (14)</td>
<td>21 (15)</td>
</tr>
<tr>
<td>Neonatologists</td>
<td>10 (5)</td>
<td>9 (6)</td>
</tr>
<tr>
<td></td>
<td>10 (5)</td>
<td>9 (6)</td>
</tr>
<tr>
<td>Obstetricians</td>
<td>92 (45)</td>
<td>62 (41)</td>
</tr>
<tr>
<td></td>
<td>88 (45)</td>
<td>58 (41)</td>
</tr>
<tr>
<td>Health strategists</td>
<td>21 (10)</td>
<td>19 (13)</td>
</tr>
<tr>
<td></td>
<td>20 (10)</td>
<td>15 (10)</td>
</tr>
<tr>
<td>Women’s representatives</td>
<td>30 (15)</td>
<td>22 (14)</td>
</tr>
<tr>
<td></td>
<td>28 (14)</td>
<td>21 (15)</td>
</tr>
</tbody>
</table>
Table 2. Prevention of PPH Core Outcome Set

<table>
<thead>
<tr>
<th>Domain</th>
<th>Outcome</th>
<th>% Consensus at Meeting* (n=20)</th>
<th>Consensus in Delphi Round 2**</th>
<th>Antenatal m2</th>
<th>Haematologist m1</th>
<th>Midwife m2</th>
<th>Neonatologist m2</th>
<th>Obstetrician m2</th>
<th>Parent Rep m2</th>
<th>Policy Maker m2</th>
<th>SAC m2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood loss assessment</td>
<td>1. Blood loss after birth</td>
<td>95%</td>
<td></td>
<td>91%</td>
<td>88%</td>
<td>95%</td>
<td>89%</td>
<td>89%</td>
<td>95%</td>
<td>79%</td>
<td>81%</td>
</tr>
<tr>
<td>Morbidity / Mortality</td>
<td>2. Shock</td>
<td>74%</td>
<td></td>
<td>100%</td>
<td>75%</td>
<td>95%</td>
<td>100%</td>
<td>97%</td>
<td>100%</td>
<td>94%</td>
<td>81%</td>
</tr>
<tr>
<td></td>
<td>3. Maternal death</td>
<td>100%</td>
<td></td>
<td>100%</td>
<td>88%</td>
<td>100%</td>
<td>100%</td>
<td>98%</td>
<td>95%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Use of additional interventions</td>
<td>4. Blood transfusion (RBC)</td>
<td>84%</td>
<td></td>
<td>100%</td>
<td>100%</td>
<td>81%</td>
<td>67%</td>
<td>97%</td>
<td>86%</td>
<td>82%</td>
<td>94%</td>
</tr>
<tr>
<td></td>
<td>5. Use of additional uterotonicis</td>
<td>90%</td>
<td></td>
<td>91%</td>
<td>86%</td>
<td>95%</td>
<td>78%</td>
<td>85%</td>
<td>76%</td>
<td>67%</td>
<td>94%</td>
</tr>
<tr>
<td>Use of resources</td>
<td>6. Transfer to higher level of care</td>
<td>79%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent reported outcomes</td>
<td>7. a) Women’s sense of wellbeing</td>
<td>79%</td>
<td></td>
<td>82%</td>
<td>88%</td>
<td>86%</td>
<td>56%</td>
<td>69%</td>
<td>95%</td>
<td>31%</td>
<td>81%</td>
</tr>
<tr>
<td></td>
<td>b) Women’s acceptability of and satisfaction with intervention</td>
<td>79%</td>
<td></td>
<td>45%</td>
<td>50%</td>
<td>43%</td>
<td>11%</td>
<td>49%</td>
<td>81%</td>
<td>44%</td>
<td>69%</td>
</tr>
<tr>
<td>Neonatal outcomes</td>
<td>8. Breastfeeding</td>
<td>79%</td>
<td></td>
<td>9%</td>
<td>13%</td>
<td>33%</td>
<td>22%</td>
<td>9%</td>
<td>52%</td>
<td>40%</td>
<td>56%</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>9. Adverse effects of intervention for mother (and baby if relevant)</td>
<td>79%</td>
<td></td>
<td>100%</td>
<td>88%</td>
<td>95%</td>
<td>78%</td>
<td>81%</td>
<td>90%</td>
<td>94%</td>
<td>94%</td>
</tr>
</tbody>
</table>

*% of participants voting outcome as critically important at Stakeholder Meeting. **% participants voting outcome as critically important among different stakeholder groups in Delphi.
Table 3. Treatment of PPH Core Outcome Set

<table>
<thead>
<tr>
<th>Domain</th>
<th>Outcome Description</th>
<th>% Consensus at Meeting* (n=20)</th>
<th>Consensus in Delphi Round 2**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Anaesthetists</td>
<td>Haematologists</td>
</tr>
<tr>
<td>Blood loss assessment</td>
<td>1. Blood loss</td>
<td>90%</td>
<td>100%</td>
</tr>
<tr>
<td>Morbidity / Mortality</td>
<td>2. Shock</td>
<td>95%</td>
<td>90%</td>
</tr>
<tr>
<td></td>
<td>3. Coagulopathy</td>
<td>74%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>4. Hysterectomy</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td></td>
<td>5. Any organ dysfunction</td>
<td>95%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>6. Maternal death</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>
| Use of additional interventions| 7. Blood transfusion a) RBC  
b) blood products                                  | a) 95%                        | 100%                          | 100%     | 95%            | 89%           | 96%          | 93%          | 100%  |
|                             | b) 74%                                                                               | 100%                          | 100%                          | 100%     | 100%           | 100%          | 98%          | 95%          | 100%  |
|                             | 8. Use of any additional haemostatic intervention                                   | 90%                           | 100%                          | 100%     | 100%           | 100%          | 98%          | 95%          | 100%  |
| Use of resources            | 9. Transfer to higher level of care                                                  | 82%                           |                              |          |                |               |              |              |       |
|                             |                                                                                      | Reconfigured                  |                              |          |                |               |              |              |       |
|                             | 10. a) Women’s sense of wellbeing  
b) Women’s acceptability of and satisfaction with intervention| a) 84%                        | 64%                           | 71%      | 61%            | 38%           | 62%          | 75%          | 40%   |
|                             |                                                                                      | b) 82%                        | 55%                           | 38%      | 65%            | 22%           | 46%          | 76%          | 53%   |
| Neonatal outcomes           | 11. Breastfeeding                                                                    | 82%                           | 18%                           | 0%       | 35%            | 44%           | 18%          | 43%          | 40%   |
|                             |                                                                                      | 18%                           | 0%                            | 35%      | 44%            | 18%           | 43%          | 40%          | 50%   |
| Adverse effects             | 12. Adverse effects of intervention on mother (and baby if relevant)                | 94%                           | 73%                           | 63%      | 75%            | 56%           | 53%          | 71%          | 27%   |

*% of participants voting outcome as critically important at Stakeholder Meeting; **% of participants voting outcome as critically important among different stakeholder groups in Delphi.
Table 4. PPH Core Outcome Sets: how to report outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>COS</th>
<th>Expert Committee Recommendations</th>
<th>Comments and Explanations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Blood loss</td>
<td>Prevention</td>
<td>Number of women with ≥500 ml AND ≤1000 ml blood loss AND median or mean* blood loss in each group, measured or estimated from birth of baby, up to cessation of active bleeding.</td>
<td>It was not possible to make recommendations on the method that should be used for blood loss assessment. Evidence is contradictory on whether outcomes are impacted by different methods used (blood loss measured or estimated). A review on this topic is currently underway. Trialists will also need to consider what methods are feasible based on their trial setting.</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td>Median or mean* blood loss in each group, measured or estimated as additional blood loss after the intervention, up to cessation of active bleeding. *</td>
<td></td>
</tr>
<tr>
<td>2. Shock</td>
<td>Prevention &amp; Treatment</td>
<td>Number of women with shock in each group, based on clinical assessment as defined by trialists.</td>
<td>Various methods have been used to assess shock and there is growing evidence on use of shock index in obstetric patients. Evidence from prospective studies is awaited before recommendations can be made on how to best assess shock.</td>
</tr>
<tr>
<td>3. Maternal death</td>
<td>Prevention &amp; Treatment</td>
<td>Number of maternal deaths in each group from all causes and maternal deaths from PPH, from randomisation up to time decided by trialists.</td>
<td>Maternal death, as defined by the World Health Organization.</td>
</tr>
<tr>
<td>4. Blood transfusion</td>
<td>Prevention &amp; Treatment</td>
<td>Number of women with any RBC blood transfusion in each group AND mean or median* RBC units transfused in each group from randomisation up to time decided by trialists. For treatment COS only, number of women with any other blood products in each group should also be reported.</td>
<td>RBC blood transfusion may also include cell salvage. Other blood products include platelets, fresh frozen plasma, and cryoprecipitate.</td>
</tr>
<tr>
<td>5. Transfer to higher level of care</td>
<td>Prevention &amp; Treatment</td>
<td>Number of women transferred to a higher level of care in each group from randomisation up to time decided by trialists.</td>
<td>A higher level of care may include transfer to hospital, higher facility, intensive care unit or specialist ward depending on trial setting.</td>
</tr>
<tr>
<td>6. Use of additional haemostatic intervention</td>
<td>Prevention</td>
<td>Number of women in whom any additional uterotonics were used in each group from randomisation up to time decided by trialists.</td>
<td>The additional haemostatic intervention will depend on what the trial intervention is. This may include additional uterotonics in trials evaluating medical treatments or surgical methods in trials evaluating more invasive methods such as balloon tamponade. The aim of this outcome is to capture failure of the trial intervention, and need for use of other treatments.</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td>Number of women in whom any additional haemostatic intervention (medical or surgical) was used in each group from randomisation up to time decided by trialists.</td>
<td></td>
</tr>
<tr>
<td>7. Hysterectomy</td>
<td>Treatment</td>
<td>Number of women who had a hysterectomy to stop bleeding in each group, from randomisation, at least up to hospital discharge.</td>
<td>Hysterectomies done specifically to stop bleeding should be reported to avoid confounding data with hysterectomies done prophylactically or for other indications.</td>
</tr>
<tr>
<td>8. Coagulopathy</td>
<td>Treatment</td>
<td>Number of women with coagulopathy in each group from randomisation up to time decided by trialists.</td>
<td>Coagulopathy should be defined as specified in annex 1 of the document WHO near miss approach for maternal health.</td>
</tr>
<tr>
<td>9. Organ dysfunction</td>
<td>Treatment</td>
<td>Number of women with any organ dysfunction in each group from randomisation up to time decided by trialists.</td>
<td>Organ dysfunction should be defined as specified in the document WHO near-miss approach for maternal health.</td>
</tr>
<tr>
<td>10. Adverse effects</td>
<td>Prevention &amp; Treatment</td>
<td>Number of women [and babies if relevant] with side effects and serious adverse effects in each group.</td>
<td>Side effects and serious adverse effects will be intervention specific, therefore should be defined by trialists as appropriate.</td>
</tr>
<tr>
<td>11. Breastfeeding</td>
<td>Prevention &amp; Treatment</td>
<td>There is a need to explore in future research studies how to best report this outcome.</td>
<td>Aspects considered important were initiation and maintenance of breastfeeding.</td>
</tr>
<tr>
<td>12. Patient reported outcomes</td>
<td>Prevention &amp; Treatment</td>
<td>There is a need to explore in future research studies how to best report these outcomes.</td>
<td>Outcomes that need qualification are a woman’s sense of wellbeing, acceptability and satisfaction with the intervention. Further research is required with women’s views on how to best report these.</td>
</tr>
</tbody>
</table>

*Report mean or median depending on data distribution; †agreed by majority view rather than consensus.